The GLP-1 Podcast Show - Dr. Michael Nauck: GLP-1 Origins | Ep. 2
Nov 03, 2025In this episode of The GLP-1 Podcast Show, Dr. Michael Nauck, Head of Clinical Research at the Diabetes Division, St. Josef-Hospital, Ruhr-University Bochum, speaks with Areesha Moiz about the origins, evolution, and therapeutic potential of incretin hormones. They cover the discovery of the incretin effect, the development of GLP-1 receptor agonists and DPP-4 inhibitors, and the expanding benefits of GLP-1–based therapies across metabolic and cardiovascular domains. Dr. Nauck also shares insights into emerging dual and triple agonists that could redefine obesity treatment. Listen now on all major platforms.
What you’ll learn:
- Incretin effect discovery
- GLP-1 therapy development
- DPP-4 inhibitors mechanism
- Cardiovascular and renal benefits
- Dual and triple agonists
Meet the guest:
Dr. Michael Nauck is Head of Clinical Research at the Diabetes Division, St. Josef-Hospital, Ruhr-University Bochum, Germany. His pioneering work on incretin hormones established the scientific foundation for GLP-1–based therapies in type 2 diabetes. With a research focus on metabolic regulation and cardiovascular outcomes, Dr. Nauck continues to advance innovation in endocrinology and obesity care.
Listen to his full conversation on The GLP-1 Podcast Show to explore the evolution and future of GLP-1–based medicine.
Liked this one? Don’t stop now. Here’s what we think you’ll love!